Activation of this non-canonical signalling pathway by DR5, which promotes tumour growth and metastasis through MAPK, PI3K/AKT or NF-κΒ signalling, is likely to be only visible in TRAIL-resistant cancer cells [12,346], including cells expressing TRAIL decoy receptors [59,372]. This evidence concerns the gene TNFRSF10B and cancer.